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Summary
Background Girls and women need effective, safe, and affordable menstrual products. Single-use products are 
regularly selected by agencies for resource-poor settings; the menstrual cup is a less known alternative. We reviewed 
international studies on menstrual cup leakage, acceptability, and safety and explored menstrual cup availability to 
inform programmes.
Methods In this systematic review and meta-analysis, we searched PubMed, Cochrane Library, Web of Science, 
Popline, Cinahl, Global Health database, Emerald, Google Scholar, Science.gov, and WorldWideScience from database 
inception to May 14, 2019, for quantitative or qualitative studies published in English on experiences and leakage 
associated with menstrual cups, and adverse event reports. We also screened the Manufacturer and User Facility 
Device Experience database from the US Food and Drug Administration for events related to menstrual cups. To be 
eligible for inclusion, the material needed to have information on leakage, acceptability, or safety of menstrual cups. 
The main outcome of interest was menstrual blood leakage when using a menstrual cup. Safety outcomes of interest 
included serious adverse events; vaginal abrasions and effects on vaginal microflora; effects on the reproductive, 
digestive, or urinary tract; and safety in poor sanitary conditions. Findings were tabulated or combined by use of 
forest plots (random-effects meta-analysis). We also did preliminary estimates on costs and environmental savings 
potentially associated with cups. This systematic review is registered on PROSPERO, number CRD42016047845.
Findings Of 436 records identified, 43 studies were eligible for analysis (3319 participants). Most studies reported on 
vaginal cups (27 [63%] vaginal cups, five [12%] cervical cups, and 11 [25%] mixed types of cups or unknown) and 
15 were from low-income and middle-income countries. 22 studies were included in qualitative or quantitative 
syntheses, of which only three were of moderate-to-high quality. Four studies made a direct comparison between 
menstrual cups and usual products for the main outcome of leakage and reported leakage was similar or lower for 
menstrual cups than for disposable pads or tampons (n=293). In all qualitative studies, the adoption of the menstrual 
cup required a familiarisation phase over several menstrual cycles and peer support improved uptake (two studies in 
developing countries). In 13 studies, 73% (pooled estimate: n=1144; 95% CI 59–84, I²=96%) of participants wished to 
continue use of the menstrual cup at study completion. Use of the menstrual cup showed no adverse effects on the 
vaginal flora (four studies, 507 women). We identified five women who reported severe pain or vaginal wounds, 
six reports of allergies or rashes, nine of urinary tract complaints (three with hydronephrosis), and five of toxic shock 
syndrome after use of the menstrual cup. Dislodgement of an intrauterine device was reported in 13 women who 
used the menstrual cup (eight in case reports, and five in one study) between 1 week and 13 months of insertion of the 
intrauterine device. Professional assistance to aid removal of menstrual cup was reported among 47 cervical cup 
users and two vaginal cup users. We identified 199 brands of menstrual cup, and availability in 99 countries with 
prices ranging US$0·72–46·72 (median $23·3, 145 brands).
Interpretation Our review indicates that menstrual cups are a safe option for menstruation management and are 
being used internationally. Good quality studies in this field are needed. Further studies are needed on cost-
effectiveness and environmental effect comparing different menstrual products.
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Introduction
Girls and women need effective, safe, and affordable 
menstrual products. Globally, an estimated 1·9 billion 
women—around 26% of the population—were of 
menstruating age in 2017, spending on average 65 days 
in the year dealing with menstrual blood flow.1 
Menstruation is a normal body function and a sign 
of reproductive health. Few solutions are available to 
manage menstruation; additionally, ignorance, prejudice, 
costs, and safety fears can impede girls and women from 
testing the full range of products available. A lack of 
affordable and effective menstrual products can result in 
leakage and chaffing in menstruating girls and women 
and can affect their health.2,3 Use of poor-quality materials 
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has been shown to predispose women to an increased 
risk of urogenital infections including bacterial 
vaginosis.4–6 In some situations, mostly researched in 
low-income and middle-income countries, menstruation 
can affect girls’ schooling,7 make women and girls a 
target of sexual violence or coercion,8,9 and affect 
employment and work experiences of women.10,11 In low-
income and middle-income countries, a lack of water, 
sanitation, and hygiene, inadequate education, and 
poor disposal facilities, raise public health concerns, 
particularly among schoolgirls.7,12 In several countries, 
the number of policy-led initiatives and donations to 
provide menstrual products have increased—eg, to keep 
girls in school. To allow such organisations to make 
informed decisions, information is needed on the full 
range of menstrual products.
The menstrual cup is not commonly known, despite its 
long history (appendix p 2).13 Like tampons, menstrual 
cups are inserted into the vagina, but the blood is 
collected in the receptacle, which can hold 10–38 mL of 
blood. The menstrual cup should be emptied every 
4–12 h, depending on menstrual flow and type of cup. 
Two types of cup are available, a vaginal cup, which is 
generally bell-shaped and placed in the vagina, and a 
cervical cup, which, like a diaphragm for contraception, 
is placed around the cervix high in the vagina. Menstrual 
cups are made of medical-grade silicone, rubber, latex, or 
elastomer and can last up to 10 years; disposable single-
use menstrual cups also exist.
We aimed to summarise current knowledge about 
leakage, safety, and acceptability of menstrual cups 
and compared, when available, with other menstrual 
products. We compiled information on global availability 
and costs of menstrual cups, did preliminary estimates 
on costs and waste savings, and examined online 
guidance materials on menarche in selected regions of 
the world for reference to menstrual cup as a product 
option.
Methods
Search strategy and selection criteria
In this systematic review and meta-analysis, we searched 
PubMed, Cochrane Library, Web of Science, Popline, 
Cinahl, Global Health database, Emerald, Google Scholar, 
Science.gov, and WorldWideScience for material in 
English from the inception of the database until 
May 14, 2019, using the keywords (“menstrual” AND “cup”) 
OR (“menses” AND “cup”) OR (“menstruation” AND 
Research in context
Evidence before this study
A lack of affordable and effective menstrual products can result 
in leakage and chaffing in menstruating girls and women 
and can affect their health and education. The number of 
programmes that provide menstrual products to assist women 
and girls has increased. The menstrual cup, a receptacle used to 
collect menstrual blood flow, has received little attention, 
which in part might reflect concerns about insertable products 
as either culturally unacceptable or because of previous public 
health alerts associated with highly absorbent tampons 
(eg, toxic-shock syndrome). Information about leakage, 
acceptability, and safety of menstrual cups is needed to support 
organisations to make informed decisions and provide more 
comprehensive menstrual health education for girls and 
women. We searched PubMed, Cochrane Library, Web of 
Science, Popline, Cinahl, Global Health database, Emerald, 
Google Scholar, Science.gov, and WorldWideScience from 
database inception on Nov 24, 2018, for publications in 
English using the keywords (“Menstrual Cup”) AND “Review” 
to determine if a review of menstrual cups was available with 
information on leakage, acceptability, and safety. No review 
was identified, but a literature review on menstrual 
management in emergency contexts noted a lack of empirical 
evidence examining the introduction and testing of menstrual 
cups in humanitarian settings.
Added value of this study
To our knowledge, this is the first systematic review and 
meta-analysis examining girls' and women’s experiences of 
menstrual cups, aggregating outcomes from 43 studies 
and 3319 participants who were asked about their use or 
willingness to use menstrual cups. We provide information on 
leakage compared with other products, a listing of known 
adverse events, and quantitative and qualitative information 
on acceptability in both high-income countries and 
low-income and middle-income countries. We also assessed 
availability and prices of menstrual cups. Serious adverse 
events were not common, with five reported cases of 
toxic-shock syndrome. However, the number of menstrual 
cup users is unknown, so comparisons of risk of toxic-shock 
syndrome between menstrual cups, tampons, or the 
intravaginal diaphragm cannot be made. Although menstrual 
cups are manufactured and available globally, they are not 
commonly mentioned on websites offering educational 
materials on puberty for girls.
Implications of all the available evidence
Menstrual cups seem to be an effective and safe alternative to 
other menstrual products. Information on menstrual cups 
should be provided in puberty education materials. Policy 
makers and programmes can consider this product as an option 
in menstrual health programmes. Further research globally can 
provide more information on acceptability and is needed to 
monitor adverse events and assess best practice to shorten 
the familiarisation phase required for safe and effective use, 
and on cost-effectiveness and environmental effects.
See Online for appendix
For initiatives in Kenya 
see http://www.gender.
go.ke/sanitary-towels-
program/
For initiatives in 
Scotland see https://
www.gov.scot/
publications/access-free-
sanitary-products-
programme-government-
commitment-business-
regulatory-impact/
pages/1/
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“cup”) OR (“vaginal” AND “cup”). We also screened the 
Manufacturer and User Facility Device Experience 
(MAUDE) database from the US Food and Drug 
Administration (FDA) for events related to menstrual cups 
(10-year limit, last search done on May 28, 2019).14 For 
information on costs and availability, we screened websites 
of menstrual cup manufacturers using different web 
listings and web searches and consulted experts (full lists 
are in the appendix [pp 35–39]).
To ensure we covered a broad range of the available 
literature, we searched the reference lists of relevant 
studies, websites of pertinent professional bodies (eg, 
FDA), non-governmental organisations, and grey literature 
(eg, reports or conference abstracts), and we contacted 
experts in the field to recommend relevant reports. For 
information on costs and availability, our search included 
individually going through every list of menstrual cup 
brands we could find and searching where they were being 
sold (via web lists, Google searches, Pinterest boards, 
Facebook pages, and experts working in countries where 
cups appeared to be unavailable to confirm).
Study eligibility, data extraction, and risk-of-bias assess- 
ment were done independently by two reviewers (AMvE 
and ML for quantitative and LM and GZ for qualitative 
studies), and conflicts were resolved via discussion until 
an agreement was reached. To be eligible for inclusion, 
the material needed to have information on leakage, 
acceptability, or safety of menstrual cups. Quantitative, 
qualitative, or mixed design studies were included. 
Animal studies, and studies using menstrual cups to 
collect vaginal fluids without participants’ reported 
experiences during menstruation were ineligible.
The main outcome of interest was menstrual blood 
leakage when using the menstrual cup. Additional 
outcomes of interest were acceptability of use of 
menstrual cups, difficulty with insertion or removal, 
comfort of wearing, and intention to use in future. Safety 
outcomes of interest included serious adverse events, 
such as toxic shock syndrome; vaginal abrasions and 
effects on vaginal microflora (eg, vaginal discharge, 
infections); effects on the reproductive, digestive, or 
urinary tract; and safety in poor sanitary conditions. 
Other safety issues we identified only during our review 
were documented, and all material was re-reviewed to 
ensure completeness of the safety assessment.
Data analysis
Data were manually extracted from studies using 
spreadsheets. If the same results from the same study 
were presented in several reports, we used data from the 
report with the largest sample size. For quality and bias 
assessments, we used the Cochrane tool for trials, an 
adaptation of the Newcastle-Ottawa tool (appendix p 5) 
for observational studies,15,16 and the Critical Appraisal 
Skills Programme tool17 for qualitative studies.
We tabulated our findings as a narrative synthesis. If 
trials or studies presented sufficiently homogeneous 
data in terms of design, we pooled results as proportions 
using meta-analyses and a random-effects model with 
heterogeneity quantified using the I² statistic (appendix 
p 3). We examined the following sources of heterogeneity 
if sufficient data were available using subgroup analysis: 
setting of the study (high-income vs low-income and 
middle-income countries), study population (adult 
women vs adolescents), year of study (study conducted 
before or after 2000), type of menstrual cup used 
(cervical vs vaginal cup), and duration of menstrual cup 
use. We assessed publication and small-study bias by 
visual inspection of funnel plots and Egger's test. We 
integrated the quantitative and qualitative analyses for 
the acceptability of use of menstrual cups.
For estimations on costs of disposable pads and tampons, 
we explored prices for commonly used products in 
six countries (the USA, the UK, India, Spain, China, 
and Canada) and calculated average costs per product. 
Extrapolating information on content and weight of 
menstrual products,18 we estimated waste and costs for a 
range of 9–25 units per product per month and compared 
these with consistent use of one menstrual cup for 
10 years. Additional information on methods used to 
assess menstrual cup information, availability and prices, 
qualitative studies, and costs and waste, and additional 
information on data extraction are in the appendix (pp 3–5).
We did a sensitivity analysis of low versus moderate-to-
good quality studies, as determined by the quality 
assessment and assessed small-study effect using funnel 
plots and the Egger's test. We used two-tailed p values of 
less than 0·05 to indicate statistical significance. We did 
statistical analyses using Metaprop, Stata version 14.2.2. 
This systematic review is registered on PROSPERO, 
number CRD42016047845.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had final responsibility to submit for 
publication.
Results
Of 436 unique records identified (appendix p 6), 59 were 
identified as relevant (figure 1), and 43 studies were 
included in our analysis (table 1). In these 43 studies, 
3319 participants used or were asked about the menstrual 
cup.5,13,14,19–73 Seven studies were completed among 
schoolgirls (ie, aged 12–19 years) in low-income and 
middle-income countries (647 [19·5%] participants).5,27,33,43,58,59 
Three studies were done in the early 1960s, six in the 
late 1980s, and 26 in 2009–18. 15 studies were from low-
income and middle-income countries. Most studies 
reported on vaginal cups (27 [63%] vaginal cups, five [12%] 
cervical cups, and 11 [25%] mixed types of cups or 
unknown) and 35 (81%) were journal articles. Although 
some studies did not report the type or brand of menstrual 
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cup used, at least seven described menstrual cups that are 
no longer available (Tassette, Tassaway, and Gynaeseal). 
The quality of quantitative studies was low, with only two 
that were of moderate-to-high quality (table 1; appendix 
pp 7–8). Many studies did not clearly identify where 
their participants were from, or participants were not 
representative of the community. Only six studies, all from 
low-income and middle-income countries, provided 
qualitative information (appendix p 10).
With regard to leakage, only four studies (n=293) made 
direct comparisons between menstrual cups and usual 
products. The outcomes in each of these studies were 
different, but leakage between products was similar in 
three studies and significantly less among menstrual 
cups for one study (figure 2).23 In studies that assessed 
menstrual cups that are still available, the proportion of 
leakage among the participants who reported use of the 
menstrual cup was 2–31% for a wide range of definitions, 
as shown in figure 2. Some factors mentioned in 
association with leakage by study authors included 
menorrhagia,48 unusual anatomy of the uterus,53 need for 
a larger size of menstrual cup,5 and incorrect placement 
of the menstrual cup, or that it had filled to capacity.39,53
When looking at safety, use of the menstrual cup was 
not associated with abnormalities in the vagina or cervix 
in three studies with vaginal examinations (n=370; 
table 2).13,52,70 Three users reported vaginal wounds in case 
reports, which could not be confirmed with medical 
records. In one case report, severe pain on removal 
was self-reported and in another case report severe pain 
was self-reported when wearing the menstrual cup,14 
and two participants in two different cohort studies 
reported vaginal or cervical irritation without clinical 
consequences.39,41 Three adverse events that were reported 
in one cohort study and three case reports were possibly 
related to an allergy; one case of silicone allergy 
necessitated reconstructive vaginal surgery.13,14,48 Difficulty 
with removal that required professional assistance—an 
adverse event we did not anticipate—was reported 
47 times for cervical cups (one participant from a cohort 
study, and 46 case reports) and twice for vaginal cups 
(both case reports).13,14,46,63
We found no increased infection risk (reproductive 
tract or systemic infection) associated with use of a 
menstrual cup among European,54,55 North American, 
and African women and girls,5,19 compared with other 
menstrual products (table 2). A decrease in candidiasis 
was reported with use of the menstrual cup in two of four 
studies that investigated this infection; one study found 
no candidiasis infections at follow-up in 18 participants, 
and the other, a randomised feasibility pilot among 
schoolgirls (aged 14–16 years) in Kenya comparing 
menstrual cups, sanitary pads, and usual practice (cloths, 
pads, tissue, or other makeshift materials), showed no 
difference in the prevalence of candidiasis by study group 
(menstrual cup 11 [8%] of 143, pads 19 [10%] of 200, and 
usual practice 13 [9%] of 156; menstrual cup vs pads 
p=0·68 and menstrual cup vs usual practice p=0·87; 
table 2).5,13,56,70 One study70 reported lower prevalence of 
bacterial infections among users of the menstrual cup 
than among users of tampons or pads (not further 
specified), and a randomised pilot study5 in Kenya 
reported lower prevalence of bacterial vaginosis among 
users of the menstrual cup than users of pads and usual 
practice enrolled for 9 months or longer (menstrual cup 
13 [13%] of 101, pads 29 [20%] of 143, usual practice 
20 [19%] of 104; menstrual cup vs pads p=0·018 and 
menstrual cup vs usual practice p=0·074; table 2).5,70 Toxic 
shock syndrome was identified in five case reports;13,14,66 
microbiological confirmation was available with cultures 
from menstrual cup and blood showing streptococcus 
Figure 1: Study selection
*Reference lists of relevant studies, websites of pertinent professional bodies 
(eg, US Food and Drug Administration), non-governmental organisations, 
grey literature (eg, reports or conference abstracts), and records recommended 
by experts. †For example, advertising approaches.
436 identified for screening
 
331 excluded after full-text 
screening
 52 cup as food measure
 6 world cup
 7 cup for eye medicine
 6 cup for breast size or 
mammogram
 35 cup for sample collection
 123 cup for vacuum extraction
 9 cupping therapy
 93 other reasons
105 full-text articles assessed for
         eligibility
46 excluded
 26 gynaecological research 
of vaginal fluids
 1 ongoing trial
 2 marketing aspects†
 9 reviews
 3 other
 5 no access
59 records from 43 studies 
eligible for inclusion
6 studies included in 
qualitative synthesis
20 studies included in 
quantitative synthesis 
(meta-analysis)
23 studies included in safety 
evaluation
44 potentially eligible records 
identified via other sources*
444 duplicates removed
836 potentially eligible studies 
identified by database search
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for one case. 14 In two participants from two case reports, 
concomitant conditions were present (intrauterine device 
[IUD] in situ; an immunodeficiency disease).14,66 A 
potential additional case of toxic shock syndrome was 
identified in a web blog (appendix pp 43–44): we could 
not determine whether this case has separately been 
reported in the MAUDE system or in a case report and 
thus it has been left out of our analysis. The prevalence of 
vaginal Staphylococcus aureus was examined among 
Kenyan schoolgirls participating in a randomised pilot 
study;5,29 no difference was seen between menstrual cup, 
pads, and usual practice groups.29 No expression of toxic 
shock syndrome toxin 1 (TSST-1) was found in S aureus 
positive samples from menstrual cup users in this 
study.29 In-vitro studies of production of TSST-1 in the 
presence of menstrual cup material showed conflicting 
results (table 2).72,73
An initial case report of a menstrual cup user about 
dislodgement of her IUD during use of a menstrual cup 
was followed by a case series of seven women who 
reported dislodgement of an IUD during removal of the 
menstrual cup between 1 week and 13 months of IUD 
insertion.14,64 A retrospective chart survey did not find an 
increased risk for IUD expulsion within 6–8 weeks after 
insertion among menstrual cup users (five [4%] of 135), 
compared with tampons users (11 [2%] of 469) or pad 
users (seven [4%] of 169).57
One case-report68 suggested use of a menstrual cup 
might have been associated with the development of 
endometriosis;68 however, this hypothesis was not 
considered plausible by the regulatory authority and 
we did not identify any further reports on this 
possible association. We found three case reports60–62 of 
hydronephrosis and one14 of incontinence when using 
the menstrual cup; however, symptoms disappeared after 
menstrual cup removal (table 2).14,60,61 Other uses of 
menstrual cups—eg, as a contraceptive or temporary 
fistula control—are in the appendix (p 9)
When assessing uptake and acceptability, all six relevant 
qualitative studies were from low-income and middle-
income countries (appendix pp 10–13),30,33,34,38,56,58,59 whereas 
20 studies with quantitative information on uptake 
and acceptability were from low-income and middle-
income countries and high-income countries (appendix 
pp 14–22).13,19,22–24,32,33,38,39,41–43,46,48,49,51–54,56 In low-income 
and middle-income countries, usual products for 
menstruation included cloths, disposable pads, cotton 
wool, tissue paper, or other items, and leakage and 
chaffing is a common concern.30,33,34,58,75 All studies that 
assessed use of menstrual cups used some form of 
education and training on the menstrual cup. Girls and 
women expressed initial concerns in qualitative studies, 
noting the size of the menstrual cup.30 Many were 
concerned it could cause pain (and noted it often did so at 
first) or worried about reproductive harms (eg, infertility). 
In quantitative studies, 3% (pooled estimate: n=1251, 
Source and 
study design
Location and 
date
Sample size 
and population
Age and heavy 
menstrual flow 
as defined by 
source
Menstrual 
cup brand* 
(type)
Comparison Follow-up Outcomes Loss to 
follow-up 
(%)
Quality 
score
Trials
Beksinska et al 
(2015)19–21
Journal article; 
individually 
randomised 
crossover
Durban, South 
Africa; 2013
110 women 29 years 
(SD 6; range 
18–45); heavy 
flow 46·2%
Mpower 
Mcup; 
(vaginal)
Usual product 
(ie, disposable 
pads, tampons, 
cloths)
6 cycles 
(3 cycles 
each 
product)
Acceptability and 
performance
4·5% 5
Hoffmann et al 
(2014)22
Journal article; 
cluster 
randomised
Jehanabad 
district, Bihar, 
India; 2012
960 women; 
174 randomly 
assigned to cup 
group and 46 
chose to use 
cup
29·9 years 
(SD 6·7); NR
NR Usual product 
(ie, cloth and 
disposable pads)
8 months Acceptability, 
demand for high-
barrier menstrual 
cup and low-barrier 
sanitary pads
15·8% 
(6 months)
4
Howard et al 
(2011)23
Journal article; 
individually 
randomised
Vancouver, 
Canada; 
2006–07
110 women; 
56 in cup group
Range 
19–40 years; 
heavy flow 11·1%
Divacup 
(vaginal)
Tampons 4 cycles Use, use in future, 
costs, and waste
11·8% 3
Oster et al (2011),24 
Oster et al (2012),25 
Oster et al (2009)26,27
Journal article; 
individually 
randomised
Bharatpur, 
Chitwan 
district, Nepal; 
2006–08
199 schoolgirls; 
98 in cup group
14·2 years 
(SD 1·2); NR
Mooncup 
(vaginal)
Usual product 
(ie, cloths and 
disposable pads)
15 months School attendance, 
peer effect
0·5% 3
Phillips-Howard et al 
(2016),5 
Nyothach et al 
(2015),28 
Juma et al (2017),29 
Mason et al (2015),30 
Oduor et al (2015),31 
van Eijk et al (2018)32
Journal article; 
cluster 
randomised
Gem district, 
Siaya Province, 
Kenya; 
2012–13
766 schoolgirls; 
229 in cup 
group
14·6 years 
(SD 0·7); heavy 
flow 20·8%
Mooncup 
(vaginal)
Disposable pads 
and usual 
practice (ie, 
cloths and pads)
Median 
10·9 
months
School drop-out, 
STIs, reproductive 
tract infections
15·7% 6
(Table 1 continues on next page)
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Source and 
study design
Location and 
date
Sample size 
and population
Age and heavy 
menstrual flow 
as defined by 
source
Menstrual 
cup brand* 
(type)
Comparison Follow-up Outcomes Loss to 
follow-up 
(%)
Quality 
score
(Continued from previous page)
Observational studies
APHRC (2010)33–35 Report; cohort 
study
Nairobi, Kenya; 
2008
36 women and 
60 schoolgirls
NR; NR Mooncup 
(vaginal)
Disposable pads, 
cloths, cotton 
wool, tampons
3 cycles Feasibility 6·3% 2
Averbach et al 
(2009)36
Journal article; 
survey and 
focus group 
discussions
Epworth, 
Zimbabwe; 
2007–08
43 women Range 
18–45 years
Duet (cervical, 
re-usable)
Cotton wool, 
cloths, 
disposable pads, 
tissue
NA Consideration of 
menstrual cup use
NA ND
Borowski et al 
(2011)37
Master's 
thesis; survey
USA; 2011 155 women Age ≥18 years; 
NR
No particular 
brand
NR NA Consideration of 
eco-friendly 
menstrual products
NA ND
Care International 
in Uganda (2018)38
Report; cohort Refugee 
settlement, 
Uganda; 2018
80 girls and 
women and 20 
female trainers
n=25 
15–18 years, 
n=41 
19–25 years, 
n=34 
26–30 years; NR
Ruby cup Disposable and 
re-usable pads, 
cloths
3 months Menstrual cup use 53·8% 2
Cattanach et al 
(1991),39 Cattanach 
et al (1990)40†
Journal article; 
cohort
Hawthorn, 
Australia; NR
80 women Range 
17–42 years; NR
Gynaeseal 
(cervical)
NR 18 months Acceptability 69·1% 2
Cheng et al (1995)41 Journal article; 
cohort
NR, Canada; 
1991–92
51 women 46 (90%) of 
51 <40 years; 
moderate to 
heavy flow: 
42 (82%) of 51
Menses cup‡ 
(vaginal)
Tampons and 
disposable pads
2–13 cycles Acceptability of 
menstrual cup for 
measuring flow
NR 2
Chintan et al 
(2017)42
Journal article; 
cohort
India (several 
sites); NR
100 women Range 
14–55 years; NR
Flow care 
(vaginal)
Disposable pads 
and tampons
8 weeks Menstrual cup use NR 2
Femme 
International 
(2017)43§
Report; cohort Kilamanjaro 
region, 
Tanzania; 
2016–17
184 adolescents 
and 38 women
Range 
12–54 years; NR
Ruby cup 
(vaginal)
NR 6–12 
months
Menstrual cup use 37–88% 2
Ganyaglo et al 
(2018),44 Ryan et al 
(2018)45
Journal article 
and abstract; 
repeated 
measures 
design
Ghana; 2016 11 women 43·6 years 
(SD 12·3); NR
Diva cup Pads 4 h Menstrual cup use 
for vesicovaginal 
fistula
0 5
Gleeson et al 
(1993)46
Journal article; 
cohort
Dublin, Ireland; 
NR
22 women NR; 12 (55%) 
women had 
menorrhagia
Gynaeseal 
(cervical)
Tampons 1 cycle Leakage, ease, use 
for measuring flow
0 3
Grose et al (2014)47 Journal article; 
survey
California, USA; 
NR
151 
undergraduates
Range 
18–23 years; NR
Brand not 
reported
NR NA Consideration of 
menstrual cup
NA ND
Kakani et al (2017)48 Journal article; 
cohort
Dharpur, 
Gujarat, India; 
NR
158 women 31 years (SD 6·1; 
range 21–50); 
heavy flow: 
20 (13%) of 150
NR: 44 mm 
diameter, thin 
walled silicon¶
Cloths, 
disposable pads, 
tampons
3 cycles Acceptability and 
efficacy
5·1% 3
Madziyire et al 
(2018)49,50§
Journal article; 
cohort
Epworth, 
Zimbabwe; 
2016–17
54 women Range 
18–45 years; no 
information on 
heavy flow
Butterfly 
(vaginal)
NR 3 cycles; 1 
year
Acceptability, 
leakage
3·7% 3
North et al (2011)13 Journal article; 
cohort
USA 
(7 centres); NR
406 women Range 
18–55 years; no 
information on 
heavy flow
Soft cup|| 
(disposable 
cervical)
Disposable pads 
or tampons, or 
both
3 cycles Safety, 
effectiveness, and 
acceptability
24·1% 3
Parker et al (1964)51 Journal article; 
cohort
Ann Arbor, 
USA; NR
65 women NR; 46 women 
with 
menorrhagia, 
19 with normal 
flow
Tassette 
(vaginal)
Tampons and 
disposable pads
2–6 months Acceptability 15·2% 3
(Table 1 continues on next page)
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Source and 
study design
Location and 
date
Sample size 
and population
Age and heavy 
menstrual flow 
as defined by 
source
Menstrual 
cup brand* 
(type)
Comparison Follow-up Outcomes Loss to 
follow-up 
(%)
Quality 
score
(Continued from previous page)
Pena et al (1962)52 Journal article; 
cohort
Florida, USA; 
NR
125 women 
(100 with 
normal flow 
and 25 with 
vaginal 
infections)
Range 
20–45 years; all 
participants had 
normal flow
Tassette 
(vaginal)
Tampons and 
disposable pads
3 cycles Not clear NR 2
Shihata et al 
(2014)53
Journal article; 
cohort
Sweden, USA, 
Mexico, Brazil, 
Colombia; 
2013
146 women Range 
18–40 years; NR
FemmyCycle 
(one size, 
vaginal)**
Disposable pads, 
tampons
3 cycles Leakage, 
acceptability
28·1% 2
Stewart et al 
(2010)54
Journal article; 
cohort
Nottingham, 
UK; 2008–09
54 women Mean 22·5 
(SD NR); NR
Mooncup 
(vaginal)
Tampons and 
disposable pads
6 cycles 
(3 with cup)
Leakage, 
acceptability
61·1% 2
Stewart et al 
(2009)55
Journal article; 
survey
Nottingham, 
UK; NR
69 clinic 
patients
n=18 <30 years, 
n=21 
30–40 years, 
n=30 >40 years; 
NR
Mooncup 
(vaginal)
Tampons and 
disposable pads
NA Consideration of 
menstrual cup
NA ND
Tellier et al (2012)56 Report; cohort 
study
Kitgum, 
Uganda; NR
31 women 24 years (SD NR); 
NR
Ruby cup 
(vaginal)
Cloths, gauze, 
disposable pads
3–5 cycles Acceptability, 
safety
51·6% 3
Wiebe et al (2012)57 Journal article; 
retrospective 
chart survey
Vancouver, 
Canada; 2009
930 women; 
96 used 
menstrual cups
75 (59%) of 
96 <30 years; NR
No particular 
brand or type
NA 6 weeks IUD expulsion 
within 6 weeks 
after placement, by 
menstrual product 
used
NA ND
Studies with only qualitative information
Hyttel et al 
(2017)58††
Journal article; 
two focus 
group 
discussions 
and six semi-
structured 
interviews
Bungatira, 
Gulu, Uganda; 
2013
36 schoolgirls 
(purposely 
selected)
14·6 years 
(SD 0·7; range 
13–17); NA
Ruby cup 
(vaginal)
NA 4 months 
after study 
start
Willingness and 
ability to use
NA Medium
Sundqvist et al 
(2015)59
Thesis; in-
depth 
interviews
Msiriwa, 
Tanzania; 2014
15 schoolgirls Range 
14–15 years; NA
Lady cup 
(vaginal)
NA NR Effect of menstrual 
cup use on 
education and 
social interactions
NA Strong
Case reports
Adedokun et al 
(2017)60
Abstract; case 
report
Brno, Czech 
Republic; NR
1 woman 30 years; NA NR NA NR Hydronephrosis NA ND
Nunes-Carneiro 
et al (2018)61
Journal article; 
case report
Porto, 
Portugal; NR
1 woman 26 years; NA NR NA 5 days Uretero-
hydronephrosis
NA ND
Stolz et al (2019)62 Journal article; 
case report
NR; NR 1 woman 47 years; NA NR NA A “couple of 
weeks”
Hydronephrosis NA ND
Day et al (2012)63 Journal article; 
case report
London, UK; 
NR
1 woman 20 years; NA Mooncup 
(vaginal)
NA NR Menstrual cup 
retention
NA ND
FDA MAUDE 
database14
Results 
database 
search; case 
reports
USA; 
1950–June, 
2018
12 women NR; NA Mooncup, Diva 
cup, Femmy 
cycle, Softcup 
(vaginal and 
cervical)
NA Variable Adverse events 
(in table 2)
NA ND
Seale et al (2019)64 Journal article; 
case series
Denver, CO, 
USA; NR
7 women n=1 16 years: n=6 
22–25 years; NA
NR NA 2–12 
months
IUD expulsion NA ND
Goldberg et al 
(2016)65
Journal article; 
case report
New 
Brunswick, 
Canada; 2013
1 woman 39 years; NA NR (vaginal) NA NR Use as diagnostic 
aid of vesicouterine 
fistula
NA ND
Mitchell et al 
(2015)66
Journal article; 
case report
Ontario, 
Canada; NR
1 woman 37 years; NA DivaCup 
(vaginal)
NA 2 weeks 
post-
admission
Possible TSS NA ND
(Table 1 continues on next page)
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95% CI 1–6%, 11 studies; I2=79·3%) of participants 
reported they could not insert the menstrual cup and 11% 
(n=1190, 95% CI 3–23%, ten studies; I2=96·4%) reported 
discontinuation related to the menstrual cup (table 3). 
Pain on insertion was reported for ten (9%) of 
106 menstrual cup users versus none of 104 using their 
usual method at 3 months of follow-up in a South African 
crossover trial (p value not reported).19 Initial discomfort 
on insertion was reported by 20% of participants (pooled 
estimate: n=1061, 95% CI 12–30%, 17 studies; I2=92·3%). 
All qualitative studies described user familiarisation with 
the menstrual cup over time, with practice, peer support, 
and training being key to success.30,33,34,38,58,59 Longitudinal 
quantitative studies in low-income and middle-income 
countries showed a learning curve of 2–5 months 
(appendix p 22); colour change of the menstrual cup as an 
objective measure suggested use increased throughout 
the first year among Kenyan schoolgirls.32 A Nepalese 
study25 noted that self-reported increased use 2 months 
after distribution was associated with the presence of 
friends who successfully used the menstrual cup. In 
India22 and Tanzania,43 the uptake of menstrual cups was 
significantly slower than uptake of pads (appendix p 24).22,43 
In 15 studies with relevant information, 73% (pooled 
estimate: n=1144, 95% CI 59–84; I2=96%) of participants 
reported willingness to continue use of the menstrual cup 
Source and 
study design
Location and 
date
Sample size 
and population
Age and heavy 
menstrual flow 
as defined by 
source
Menstrual 
cup brand* 
(type)
Comparison Follow-up Outcomes Loss to 
follow-up 
(%)
Quality 
score
(Continued from previous page)
Russell et al (2016)67 Journal article; 
case reports
Utah, USA; NR 3 women 54 years, 
60 years, and 
68 years; NA
NR (vaginal) NA NR Use as 
enterovaginal or 
vesicovaginal 
fistula control
NA ND
Spechler et al 
(2003)68
Journal article; 
case report
Bethesda, MD, 
USA; NR
1 woman 41 years; NA Keeper 
(vaginal)
NA 2 years 
post-
surgery
Adenomyosis and 
endometriosis
NA ND
Other types of study with relevant information
Cattanach et al 
(1989)69†
Journal article; 
vaginal 
samples
Hawthorn, 
Australia; 
1986–88
5 women Range 
19–32 years; NA
Gynaeseal* 
(cervical)
NA 3–22 
months
Menstrual cup 
safety, effect on 
vaginal flora
NA ND
Karnaky et al 
(1962)70
Journal article; 
vaginal 
observations 
and samples
Houston, 
TX,USA; NR
Two cohorts of 
50 and 
97 women; and 
a survey of 
20 women
NR; NA Tassette 
(vaginal)
NA Unclear for 
cohort 
studies
Menstrual cup 
safety, effects on 
vagina
NA ND
Tierno et al (1989)71 Journal article; 
in-vitro study
New York, NY, 
USA; NR
NA NA; NA 16 menstrual 
cups, brands 
not reported
NA NA Ability to induce 
TSST-1 production 
by TSS-associated 
strains of 
Staphylococcus
NA ND
Tierno et al (1994)72 Journal article; 
in-vitro study
New York, NY, 
USA; NR
NA NA; NA Six Tassaway 
cups (vaginal)
NA NA Ability to induce 
TSST-1 by a TSS 
strain of 
Staphylococcus 
aureus MN8
NA ND
Nonfoux et al 
(2018)73
Journal article; 
in-vitro study
France; NR NA NA; NA 2 be’Cup and 2 
MeLuna 
(vaginal)
NA NA Effect on S aureus 
growth and TSST-1 
production using 
the modified sac 
method
NA ND
Where data are missing, it was not provided in the source material. Cycles refer to menstrual cycles. A quality score of 5–6 indicates a moderate-to-high quality study, and a score of less than 5 indicates a 
medium-to-low quality study. For qualitative studies, levels of study quality were strong, medium, and weak. The quality score components of individual studies are in the appendix (pp 7, 8, 10). Cloths=pieces of 
material (clothing, blankets, socks) that are used for menstruation and can be reused after washing or disposed of after use. NR=not reported. STI=sexually transmitted infection. APHRC=African Population and 
Health Research Center. NA=not applicable. ND=not done (these studies were not assessed for quality). IUD=intrauterine device. FDA=US Food and Drug Administration. MAUDE=Manufacturer and User Facility 
Device Experience. TSS=toxic shock syndrome. TSST-1=toxic shock syndrome toxin 1. *Manufacturing company, city, country, and website where available, are listed in the appendix (p 8). †The study author was 
the developer of Gynaeseal (a disposable cup covering the cervix. that can also be worn during intercourse); we assumed the articles from 1990 and 1991 described the same study and used the publication with 
the larger sample size (1991). ‡This type of cup has a drainage tube that can be opened to let menstrual fluids pass. §Additional information obtained from internal report or author. ¶Description in article is like 
a cervix-covering cup (“The device- the menstrual cup we utilized for the study is an internally worn device with a pliable rim 44mm in diameter and a thin-walled reservoir to collect and hold the menstrual fluid. 
It was designed to minimize bulk in order to facilitate insertion and removal. Once inserted; it opens to an oval shape, positioned between the posterior fornix and the notch behind the pubic bone, covering the 
cervix. Removal is accomplished by hooking a finger over the rim behind the pubic bone. It is made up of health grade non-toxic non- allergic silicon”), but image is of a low vaginal cup. ||Instead Softcup 
(a rebrand of Softcup): disposable cup covering the cervix. This type of cup can also be worn during intercourse. **Author has patent on this menstrual cup. ††Part of a larger study (Gulu Schoolgirl 
Menstrual Cup Study, n=194), for which no other publication could be retrieved.
Table 1: Characteristics of studies contributing to menstrual cup review
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after the study (figure 3). All qualitative and some 
quantitative studies reported a positive effect of use of the 
menstrual cup on participants’ lives, decreased stress 
concerning staining and leakage, and improvements in 
mobility.13,51,53 Challenges described included difficulties 
with cleaning and storage of the menstrual cup in 
low-income and middle-income countries.34,58 Other 
challenges were associated with emptying the menstrual 
cup in school or public toilets,28,34,58 which was also reported 
by participants in high-income countries.37 Menstrual 
cups were associated with a decrease in the average 
number of changes per cycle in a UK study compared 
with tampons or sanitary pads.54 Three qualitative studies 
implied that school attendance, concentration, and 
performance improved after participants were given a 
menstrual cup.30,34,58 No measured difference in school 
absence or test results between products were reported 
(appendix p 24).5,27,34 A study in Nepal noted a significant 
decrease in time spent doing laundry for menstrual cup 
users compared with those using usual practice.27
An economic advantage of a menstrual cup emerged in 
qualitative studies, with participants (and families) citing 
monthly cost savings from not needing to purchase pads 
or soap for laundry. Two qualitative studies included 
quotes from participants showing that menstrual cups 
might decrease the need for transactional sex to purchase 
pads.34,38 This finding might be corroborated by results 
from a randomised controlled study among schoolgirls 
(aged 14–16 years) in rural western Kenya that noted a 
significantly lower prevalence of sexually transmitted 
infections among participants who were provided by the 
study with either menstrual cups or disposable pads 
versus controls (ie, using usual practice), citing lower 
exposure to transactional sex as a probable reason 
(table 2; appendix p 24).5
A study in schoolgirls in Kenya (aged 14–16 years) in an 
area with poor water and sanitation76 reported dropping 
of menstrual products during changing of cloths or 
disposable pads, or emptying of the cup.31 The frequency 
was similar for menstrual cups and sanitary pads. Factors 
involved included young age, and lack of time and 
privacy. Dropping of the menstrual cup decreased with 
increasing experience (approximately 23% in the first 
3 months and 10% at or after 12 months). This dropping 
was associated with Escherichia coli isolated in cultures 
from swabs of menstrual cups, which was higher in new 
users than in experienced users (table 2).29 The proportion 
of girls who washed their hands before changing of the 
menstrual cup, by verbal self-report, was 95% (204 of 215) 
in a Kenyan report,28 70% (16 of 23) in a Ugandan report,56 
and 94% (15 of 16) in a study in a refugee camp.38 When 
toilets have a lack of water, some participants reported 
carrying a bottle of water for when they emptied their 
menstrual cup.28 Others said they had to empty the 
Figure 2: Menstrual cup and leakage
(A) Proportion of participants who had menstrual leakage in seven studies using different types of menstrual cups and definitions. (B) Reports of leakage among 
menstrual cup users versus users of other menstrual products. APHRC=African Population and Health Research Center. NR=not reported. *Disposable pad or tampon. 
†Likert scale: 7-point score, in which 1=terrible and 7=great. ‡p value reported in article for Mann-Whitney test.
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n (%) or description Notes Data source
Handling and positioning of menstrual cup
Vaginal wound
Cup not clear 
(Divacup or softcup)
Event April, 2012; vaginal wound due to use of menstrual cup, 
needing treatment from physician for vaginal bleeding
Complete medical records were not available for evaluation FDA database14
Softcup (cervical) Reported April, 2012; long-term customer of softcup product 
claimed vaginal scarring due to use
Medical director did not find anything in medical records provided by 
customer related to vaginal health
FDA database14
Softcup (cervical) FDA database case report: “…cup wore through the vaginal wall, 
damaging an artery that required surgical repair”
Event could not be confirmed; no medical records were available North et al (2011)13
Vaginal pain on removal
Divacup (vaginal) Event March, 2017; extreme pain on removal (first use), 
individual stopped using the cup
Self-report; no medical report available FDA database14
Pelvic pain
Softcup (cervical) Event February, 2017; pain in lower pelvis and rectum and nausea 
about 1 h after insertion, no longer present approximately 
30 min after removal
Self-report; no medical evaluation available; individual stopped use after 
trying twice (possibly vascular compression)
FDA database14
Vaginal irritation
Gynaeseal (cervical) One (1%) of 73 Self-report by participant Cattanach et al 
(1991)39
Cervix irritation
Menses cup (vaginal) One (2%) of 51 Cervical smear was normal Cheng et al 
(1995)41
Allergy and rash
NR, vaginal cup Allergy: one (1%) of 150; and rash: two (1%) of 150 · · Kakani et al 
(2017)48
Softcup (cervical) FDA database: two case reports NR North et al (2011)13
Mooncup (vaginal) Event 2010: silicone allergy in one individual Surgery was needed for vaginal repair; manufacturer noted that silicone 
allergy is very rare
FDA database14
Difficulty with removal requiring professional assistance
Gynaeseal (cervical) One (5%) of 22 · · Gleeson et al 
(1993)46
Softcup (cervical) FDA database: three case reports reported by North 2011; 
one event in 2018
· · North et al 
(2011),13 FDA 
database14
Softcup (cervical) Reported complaints to company 2003–08: 42 individuals 
underwent physician-assisted removal
Other complaints reported to company included poor fit (n=102), 
leakage (n=168), messy (n=98)
North et al (2011)13
Mooncup (vaginal) Case report: menstrual cup lodged on cervix, difficult to remove, 
requiring assistance
Moderate cervical inflammation after retrieval Day et al (2012)63
Divacup (vaginal) Event April, 2015: one case report required an emergency room 
visit for removal
· · FDA database14
Reproductive tract observations with use of menstrual cup
Vulva abnormalities
Softcup (cervical) Baseline: four (1%) of 393; cycle 1: eight (2%) of 365; cycle 2: 
six (2%) of 326; cycle 3: five (2%) of 305
Vulva-vaginal inspection at baseline and monthly for 3 months; no p values 
reported
North et al (2011)13
Abnormalities of vaginal wall
Softcup (cervical) Zero of 44 Vulva-vaginal inspection at baseline and monthly for 3 months North et al (2011)13
Tassette (vaginal) Zero of 12 Vaginal inspection after 3 months Pena et al (1962)52
Tassette (vaginal) Zero of 50 Vaginal inspection done; timing of inspections not clear Karnaky et al 
(1962)70
Abnormalities of cervix
Softcup (cervical) Baseline: 23 (6%) of 390; cycle 1: ten (3%) of 345; cycle 2: six (2%) 
of 326; cycle 3: four (1%) of 300
Inspection of cervix; no p values reported for differences North et al (2011)13
Softcup (cervical) Abnormal cervical smear test: baseline: one (<1%) of 406; cycle 1: 
one (<1%) of 368; cycle 2: two (1%) of 329; cycle 3: zero of 308
Abnormal cervical smear test results were exclusion criteria at admission, and 
a reason for discontinuation of the study; no p values reported for differences
North et al (2011)13
Condition of vaginal and cervical epithelium
Softcup (cervical) 44 women examined at baseline, 37 at 2–3 months, and 25 at 
5–6 months
“The Softcup caused no alteration or disruption in vaginal or cervical 
epithelium, as assessed by colposcopy and cervical cytology”
North et al (2011)13
(Table 2 continues on next page)
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n (%) or description Notes Data source
(Continued from previous page)
Vaginal flora and infections with use of menstrual cup
pH changes of vagina
Tassette (vaginal) Zero of 50 No abnormalities, vaginal areas where menstrual cup was placed were 
more acid
Karnaky et al 
(1962)70
Softcup (cervical) Mean pH at baseline: 4·6 (n=400); cycle 1: 4·6 (n=368); 
cycle 2: 4·6 (n=329); cycle 3: 4·5 (n=308)
No p values reported North et al (2011)13
Clue cells (vaginal smear) Lactobaccilus
Softcup (cervical) Number with clue cells: baseline n=6; cycle 1 n=6; cycle 2 n=2; 
cycle 3 n=4
Sample sizes and p values were not reported North et al (2011)13
Lactobaccilus
Softcup (cervical) “…before, during, and after use of the cup, vaginal Lactobacillus 
(normal vaginal flora) was maintained at normal levels.”
Data in figure 3 in publication cannot be extracted; no significant changes 
according to authors
North et al (2011)13
Gardnerella vaginalis
Softcup (cervical) No significant changes from baseline-cycle 3 according to authors Data in figure 3 in publication cannot be extracted North et al (2011)13
Bacterial vaginosis
Softcup (cervical) No significant changes from baseline to cycle 3 according to 
authors
Data in figure 3 in publication cannot be extracted North et al (2011)13
Mooncup (vaginal) Study end survey: cup 21 (15%) of 144; pads 40 (20%) of 202, and 
usual practice (control) 32 (21%) of 156; cup vs control p=0·11 and 
cup vs pads p=0·13; among girls enrolled for ≥9 months: cup 13 
(13%) of 101, pads 29 (20%) of 143, usual practice 20 (19%) of 
104; cup vs control p=0·07, and cup vs pads p=0·018
Cluster randomised trial of schools; median follow-up 11 months 
(range 3–15)
Phillips-Howard 
et al (2016)5
Candidiasis
Softcup (cervical) Number with candidiasis: baseline n=6; cycle 1 n=6; cycle 2 n=3; 
cycle 3 n=6
Sample sizes not reported; according to authors, yeast decreased significantly 
from month 1 to 2
North et al (2011)13
Ruby cup (vaginal) Zero of 18 participants had vaginal candidiasis at follow-up 
(3–5 months)
NA Tellier et al (2012)56
Tassette (vaginal) Candida albicans decreased with the use of the cup NR Karnaky et al 
(1962)70
Mooncup (vaginal) Study end survey: cup 11 (8%) of 143, pads 19 (10%) of 200, usual 
practice (control) 13 (9%) of 156; cup vs control p=0·87, and cup 
vs pads p=0·68
Cluster randomised trial of schools; median follow-up 11 months 
(range 3–15)
Phillips-Howard 
et al (2016)5
Group B Streptococcus
Softcup (cervical) No differences between baseline and cycle 1 to cycle 3 Data in figure 3 in publication cannot be extracted; no significant changes 
according to authors
North et al (2011)13
Enterococcus
Softcup (cervical) Increase in Enterococcus from cycle 2 to cycle 3 (p=0·03 ) “… this increased frequency persisted for 3 months after discontinuing use of 
the cup, suggesting that factors or behavior other than cup use may have 
influenced colonization”; data in figure 3 in publication cannot be extracted
North et al (2011)13
E coli
Softcup (cervical) No significant changes from baseline to cycle 3 according to 
authors
Data in figure 3 in publication cannot be extracted North et al (2011)13
Escherichia coli on menstrual cup
Mooncup (vaginal) Nine (53%) of 17 if used cup for <6 months; four (22%) of 18 if used 
for ≥6 months (p=0·12); association between E coli with heavy 
periods: 61·5% of girls reporting heavy periods had E coli on cups, 
compared with 22·7% of those stating they did not have heavy 
periods (p=0·022, no numbers presented)
Cluster randomised trial of schools; median follow-up 11 months (range 
3–15)
Juma et al (2017)29
Chlamydia trachomatis
Mooncup (vaginal) Study end survey: cup three (2%) of 144, pads three (2%) of 201, 
usual practice (control) seven (5%) of 154; cup vs control p=0·20, 
and cup vs pads p=0·63
Cluster randomised trial of schools; median follow-up 11 months (range 
3–15)
Phillips-Howard 
et al (2016)5
Trichomonas vaginalis
Softcup (cervical) Zero cases at baseline, and cycles 1 to 3 Sample sizes not reported North et al (2011)13
Mooncup (vaginal) Study end survey: cup two (1%) of 143, pads five (3%) of 200, 
usual practice (control) seven (5%) of 154; cup vs control p=0·12, 
and cup vs pads p=0·36
Cluster randomised trial of schools; median follow-up 11 months 
(range 3–15)
Phillips-Howard 
et al (2016)5
(Table 2 continues on next page)
Articles
12 www.thelancet.com/public-health   Published online July 16 2019   http://dx.doi.org/10.1016/S2468-2667(19)30111-2
n (%) or description Notes Data source
(Continued from previous page)
Ruby cup (vaginal) Zero of 18 at baseline, and at 3–5 months of follow-up NA Tellier et al (2012)56
Neisseria gonorrhoea
Mooncup (vaginal) Study end survey: cup one (1%) of 144, pads one (1%) of 201, 
usual practice (control) one (1%) of 154; cup vs control p=0·96, 
and cup vs pads p=0·81
Cluster randomised trial of schools; median follow-up 11 months 
(range 3–15)
Phillips-Howard 
et al (2016)5
Ruby cup (vaginal) Zero of 18 at baseline, and at 3–5 months of follow-up NA Tellier et al (2012)56
Staphylococcus aureus
Softcup (cervical) No significant changes in cycles 1–3 compared with baseline Data in figure 3 of publication cannot be extracted North et al (2011)13
Mooncup (vaginal) Among menstrual cup users: four (11%) of 38 in first month of 
intervention, 13 (9%) of 139 after first month; p=0·83 
(median follow-up 4 months, range 2–11 for this substudy); 
prevalence was 21 (11%) of 197 in sanitary pads group, and 
16 (11%) of 153 in usual practice group
Cluster randomised trial in schools; median follow-up 11 months 
(range 3–15); samples from vaginal swab (self-swabbing)
Juma et al (2017)29
be’Cup (vaginal) Silicone cup: potentially more S aureus after incubation for 8 h 
with shaking in a plastic bag with S aureus in one of two cups used, 
but not when no shaking
In-vitro study Nonfoux et al 
(2018)73
Me Luna (vaginal) Thermoplastic isomer cup: no more S aureus after incubation for 
8 h with shaking in plastic sac, and not when no shaking
In-vitro study Nonfoux et al 
(2018)73
TSST-1
Mooncup (vaginal) 49 schoolgirls with vaginal S aureus had second swab: ten yielded 
S aureus, two had TSST-1, both in sanitary pad group; the cases 
were asymptomatic
Cluster randomised trial in schools; median follow-up 11 months 
(range 3–15); sample from vaginal swab (self-swabbing)
Juma et al (2017)29
NR No TSST-1 in supernatant of S aureus cultivated for 24 h 
(incubated aerobically in a still growth environment) in the 
presence of elastic polymer menstrual cup (n=16 menstrual cups)
In-vitro study Tierno et al 
(1989)71
Tassaway (vaginal) S aureus MN8 produced no TSST-1 when grown in the presence of 
Tassaway (elastomeric polymer, n=6), washed or unwashed, no 
shaking, incubation overnight
In-vitro study Tierno at al 
(1994)72
be’Cup (vaginal) Silicone cup: potentially more TSST-1 production after incubation 
for 8 h with shaking in plastic bag with S aureus compared with 
control, but not when not shaken or with pieces of cup
In-vitro study Nonfoux et al 
(2018)73
Me Luna (vaginal) Thermoplastic isomer cup: potentially more TSST-1 production 
after incubation for 8 h with shaking in plastic bag with S aureus 
compared with control, but not when not shaken or with pieces 
of cup
In-vitro study Nonfoux et al 
(2018)73
TSS
Mooncup (vaginal) Zero of 192 in trial in Kenya “Safety monitoring components comprised routine nurse-based screening, 
population-based monitoring (school and community) and clinical 
evaluation of infection with laboratory confirmation”
Juma et al (2017)29
Softcup (cervical) Two case reports in the FDA database Both unconfirmed cases of TSS North et al (2011)13
Divacup (vaginal) One case report: blood cultures and urine culture negative, 
no culture of the menstrual cup was done
Woman had history of Hashimoto’s thyroiditis and chronic menorrhagia Mitchell et al 
(2015)66
Mooncup (vaginal) Event February, 2012: TSS 2 days after using of first and new 
Mooncup resulting in 9 days of inpatient hospital stay; 
vaginal swab positive for S aureus
Had an IUD, Mooncup was not sent for bacteriological testing FDA database14
Divacup (vaginal) Event February, 2015: TSS from Streptococcus resulting in 5 days 
of i-patient hospital stay; culture of cup isolated group A and 
B streptococcus
Woman had used Divacup for menstrual period, which started 3 days before 
illness; menstrual cup was in for 18 h on admission to hospital
FDA database14
UTI
Ruby cup (vaginal) Baseline: four (13%) of 31; at follow-up (after 3–5 months) 
three (17%) of 18; p=0·65, McNemar test
One participant with a UTI at enrolment and follow-up had her cup stolen 
and used toilet paper in vagina as a tampon
Tellier et al (2012)56
Gynaeseal (cervical) One (1%) of 73 had transient dysuria “The woman who developed dysuria did not seek treatment and the problem 
subsided within 24–48 hours”
Cattanach et al 
(1991)39
Softcup (cervical) Urine analysis done; detailed results not reported “Monthly monitoring of gynecological health via urinalysis, pelvic 
examination with visual evaluation of tissues, vaginal pH, and microscopic 
wet mount showed no adverse effects of cup use”
North et al (2011)13
Softcup (cervical) Event August, 2014: UTI confirmed by urine cultures twice after 
use of softcup
Medical records were not available for evaluation FDA database14
(Table 2 continues on next page)
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Infections overall
Tassette (vaginal) “The amount of bacterial contamination was greatest with the 
pad, next with the tampon and least with the rubber cup”
No data provided; study reported to make cultures from vaginal wall samples 
and to examine fresh and stained smears for C albicans, Trichomonas vaginalis, 
Haemophilus vaginalis, and for predominance of Gram-positive or 
Gram-negative cocci, small rods or long-rod bacilli (Doederlein bacilli)
Karnaky et al 
(1962)70
Softcup (cervical) FDA database: one case report Vaginal infection not further specified; could not be confirmed at follow-up North et al (2011)13
Butterfly cup 
(vaginal)
“...none of the women sought treatment for a pelvic infection.
There was no onset or worsening of dysmenorrhoea in 83%, 
dyspaurenia in 94%, pelvic pain in 92% and vaginal discharge 
in 92% of the participants during the 12 months of 
cup use"; n=52
NA Madziyire et al 
(2018)49,50
Gynaeseal “There was no increased pathogenicity detected in vaginal flora. 
There was a trend towards smaller numbers of potentially 
pathogenic bacteria for 4 of the women, and the remaining 
woman showed no change. None of the women developed any 
significant medical problems"
Vaginal swabs before and after use, five women, median follow-up 
14 months (range 3–22)
Cattanach et al 
(1989)69
STIs
Mooncup (vaginal) Study end survey: menstrual cup six (4%) of 144, 
pads nine (5%) of 202, and usual practices (control) 
12 (8%) of 156; cup vs control p=0·11, and cup vs pads p=0·87; 
when follow-up was ≥9 months: cup four (40%) of 101, 
pads seven (5%) of 143, and usual practice 11 (11%) of 104; 
cup vs control p=0·004, and cup vs pads p=0·60
Presence of either C trachomatis, T vaginalis or N gonorrhoea; cluster 
randomised trial of schools in Kenya; median follow-up 11 months 
(range 3–15)*
Phillips-Howard 
et al (2016)5
Reproductive tract infections
Mooncup (vaginal) Study end survey: cup 31 (22%) of 144, pads 58 (29%) of 202, and 
usual practice (control) 42 (27%) of 156; cup vs control p=0·36, 
and cup vs pads p=0·19
Presence of either B vaginosis or C albicans; cluster randomised trial of schools 
in Kenya; median follow-up 11 months (range 3–15)
Phillips-Howard 
et al (2016)5
Other adverse events
Urinary incontinence
Femcap (first model 
of femmycycle, 
vaginal)
FDA database: one case report; event July, 2014; pelvic pain and 
urinary incontinence when wearing and removing menstrual cup; 
urine sample negative for infection
Self-report; stopped using menstrual cup FDA database14
Displacement of IUD when using menstrual cup
NR IUD expulsion 6–8 weeks after insertion: menstrual cup five (4%) 
of 135, tampon 11 (2%) of 469, pads: seven (4%) of 169; cup vs 
tampon p=0·57, and cup vs pads: p=0·92
Retrospective cohort; expulsion of an IUD occurs in approximately one in 
20 women and is most common in the first 3 months after insertion; 
expulsion commonly occurs during menstruation; some recommend not to 
use internal sanitary protection for 3–6 weeks after insertion because of an 
increased infection risk
Wiebe et al 
(2012)57
Mooncup (vaginal) FDA database: one case report; event July, 2012; potential IUD 
dislodgment after Mooncup removal; patient had an ectopic 
pregnancy and needed surgery
Patient felt pain after removal of Mooncup and had the position of the IUD 
checked at a health centre where it was declared in position; 2 months later 
she was found to be pregnant
FDA database14
NR Case series of seven women with IUD expulsion when removing 
menstrual cup; expulsion occurred 1 week to 13 months after 
insertion of IUD and was recurrent in two women; of seven women, 
two choose to use different contraception; the five others had their 
IUD re-inserted
Two women opted for cutting the wires of the IUD close to the cervix to 
avoid the problem; authors also stress importance of releasing vacuum of 
menstrual cup before removal
Seale et al (2019)64
Endometriosis because of menstrual backflow via use of menstrual cup
Tassette (vaginal) Position of cup confirmed with X-ray imaging "Hence the free space available in the upper vagina plus the capacity of the 
cup itself are ample to accommodate several times the amount of blood 
passed in a complete menstrual cycle"
Pena et al (1962)52
Tassette (vaginal) No evidence for backflow “Thin watery solutions could not be introduced under high pressures during 
the menstrual flow in 6 multiparous women”
Karnaky et al 
(1962)70
Keeper (vaginal) Case report: dysmenorrhoea 2 years after start of menstrual cup use 
(10 years ago tubal ligation); laparoscopy showed adenomyosis and 
endometriosis, treated with laser; patient stopped use of menstrual 
cup; pain decreased after surgery; 2 years of follow-up
“The observations in our patient suggest that it may be useful to inquire 
about use of these devices in women with pelvic pain or endometriosis”; 
petition for revoking of market approval to US FDA rejected because of lack 
of evidence74
Spechler et al 
(2003)68
(Table 2 continues on next page)
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menstrual cup only twice a day, so they could avoid 
emptying in public places.38 In two studies, women 
reported that use of menstrual cups saved water because 
of less leaking and washing of cloths.33,38 Privacy was 
mainly mentioned as a problem when boiling (ie, 
cleaning) or storing menstrual cups.38,56
We identified considerable heterogeneity in outcomes 
of acceptability of menstrual cups in the pooled meta-
analyses (table 3). Subgroup analyses by study quality 
(low vs moderate-to-good) for outcomes examined did not 
show significant differences for the outcomes examined, 
but the sample size for moderate-to-good quality studies 
was small (appendix p 23). Smaller studies sometimes 
show different, often larger, treatment effects than large 
studies (ie, small-study effect); except for the outcome of 
"could not insert cup" (p=0·041), we did not find evidence 
for the presence of small-study effects (appendix p 23).
In the assessment of visibility in three studies in 
high-income countries, only 11–33% of the women 
interviewed (n=375) were aware of menstrual cups 
(appendix p 25).37,47,55 On 69 websites with educational 
materials on puberty and menarche from 27 countries, 
disposable pads were mentioned as an option by 53 (77%), 
tampons by 45 (65%), menstrual cups by 21 (30%), and 
reusable pads by 15 (22%; appendix pp 26–28). In the 
assessment of costs and availability, we identified 
199 brands of menstrual cups, and availability in 
99 countries with prices ranging US$0·72–46·72 
Pooled prevalence Number 
of studies 
(or subgroups)
Total 
participants
I2 pheterogeneity p value 
for Z test*
Could not insert cup 2·8% (0·8–5·6) 11 1251 79·3% <0·0001 0·0002
Used menstrual cup at least once (verbal report) 79·3% (68·5–88·4) 25 2367 97·1% <0·0001 <0·0001
Menstrual cup-related discontinuation 10·7% (2·7–22·6) 10 1190 96·4% <0·0001 0·0004
Discontinuations for other reasons 9·0% (3·8–15·9) 15 1783 94·9% <0·0001 <0·0001
Difficult to insert (among users) 20·3% (11·7–30·4) 17 1061 92·3% <0·0001 <0·0001
First cycle 35·3% (15·4–58·1) 5 272 92·7% <0·0001 <0·0001
Later cycles† 13·0% (8·1–18·7) 12 789 74·3% <0·0001 <0·0001
Uncomfortable to wear 12·6% (5·9–21·3) 12 958 91·9% <0·0001 <0·0001
First cycle 32·9% (2·2–76·2) 3 221 97·5% <0·0001 0·0148
Later cycles‡ 7·9% (4·0–12·9) 9 737 77·1% <0·0001 <0·0001
Difficulty removing 9·3% (2·9–18·3) 7 461 84·7% <0·0001 0·0001
Continue using the cup 72·5% (59·0–84·3) 15 1144 95·6% <0·0001 <0·0001
Study before 2000 68·5% (16·1–100) 4 241 98·4% <0·0001 0·0014
Study after 2000§ 73·8% (63·0–83·3) 11 903 91·5% <0·0001 0·0001
Data in parentheses are 95% CIs. No significant difference was found for any of the subgroup analyses (high-income vs low-income and middle-income countries, 
adult women vs adolescents, type of cup, duration of follow-up, or high vs low or moderate study quality). *A significant Z test indicates that the pooled prevalence is 
different from zero. †Difficult to insert: first vs later menstrual cycles: p=0·15. ‡Uncomfortable to wear: first vs later menstrual cycles: p=0·13. §Continue to use cup: before vs 
after 2000: p=0·29.
Table 3: Pooled estimates of meta-analyses for different outcomes of acceptability
n (%) or description Notes Data source
(Continued from previous page)
Hydronephrosis (ie, renal colic)
NR Case report: severe colicky flank pain; CT scan showed menstrual 
cup was slightly dislocated, pressing into left ureter
“The extraction of the menstrual cup resulted in resolution of 
hydronephrosis and associated symptoms”
Adedokun et al 
(2017)60
NR Case report: 3 h of back pain on the right side; low-dose 
unenhanced CT scan showed entrapment of left vaginal wall and 
part of interolateral bladder wall; improperly positioned 
menstrual cup
Symptoms and swelling disappeared after removal of menstrual cup, 
confirmed by another CT scan; patient had used a menstrual cup for a long 
time with no previous problems, and continued use of cup; no problems at 
follow-up after several weeks
Stolz et al (2019)62
NR Case report: 3 h of pain in the right flank, and nausea during 
menstruation; X-ray imaging showed menstrual cup orientated to 
the right
“The symptoms and the ureterohydronephrosis relieved completely after the 
removal of the device”; patient had used a menstrual cup for 2 years
Nunes-Carneiro 
et al (2018)61
Entries in FDA database14 for softcup not entered if before 2011, to avoid double reporting with North et al (2011).13 NR=not reported. NA=not applicable. TSST-1=toxic shock syndrome toxin-1. TSS=toxic shock 
syndrome. FDA=US Food and Drug Administration. IUD=intrauterine device. UTI=urinary tract infection. STI=sexually transmitted infection. *The decrease in STIs in the trial in Kenya in the groups in which either 
menstrual cups or sanitary pads were provided is thought to be an indirect effect because of the decrease in risky sexual behaviour to obtain money to buy pads.
Table 2: Safety and side-effects of the menstrual cup
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(median 23·3 [IQR 16·54–29·20], from 145 brands with 
prices available; appendix pp 29–39).
When considering financial and environment costs, 
using accumulated estimates over 10 years, purchase costs 
and waste from consistent use of a menstrual cup (vaginal 
cup) would be a small fraction of the purchase costs and 
waste of pads or tampons—eg, if compared with using 
12 pads per period, use of a menstrual cup would 
comprise 5% of the purchase costs and 0·4% of the plastic 
waste, and compared with 12 tampons per period, use of a 
menstrual cup would comprise 7% of the purchase costs 
and 6% of the plastic waste (appendix pp 40–42).
Discussion
Women, girls, and transgender people require hygienic 
menstrual products monthly to live healthy and productive 
lives. In this systematic review and meta-analysis, we 
assessed the menstrual cup, combining information from 
medical and grey literature to inform choice and 
strengthen the evidence base for programmes supporting 
menstrual health, such as for schoolgirls in low-income 
and middle-income countries or among refugees. Leakage 
was similar or less when using the menstrual cup than 
when using disposable pads and tampons. The adoption 
of a menstrual cup required a familiarisation phase and 
peer support seemed to be important for uptake in low-
income and middle-income countries. Challenges in 
resource constrained settings (eg, lack of sanitation, 
hygiene, and privacy) did not stop women from using the 
cup. Around 70% of participants in 13 studies declared 
wanting to continue use. We identified several incidental 
case reports of vaginal damage, toxic shock syndrome, or 
urinary tract complaints after menstrual cup use, and 
difficulty retrieving the menstrual cup was also reported. 
Use of menstrual cups has been described as a factor for 
IUD dislodgement. Menstrual cups were infrequently 
mentioned in online educational materials on puberty 
and menstruation for adolescent girls; the lack of 
information appears to be global. Brands of menstrual 
cups were identified in 99 countries with a wide range in 
prices with a median of US$23·30.
In studies that examined the vagina and cervix during 
follow-up, no mechanical harm was evident from use of a 
menstrual cup.13,52,70 Infection risk did not appear to 
increase with use of a menstrual cup, and compared with 
pads and tampons, some studies indicated a decreased 
infection risk.5,13,70 A study in Kenya that detected lower 
bacterial vaginosis in users of a menstrual cup than in 
those who used sanitary pads postulated that the inert 
material of the menstrual cup might assist in maintaining 
a healthy vaginal pH and microbiome.5 Reported pain 
might relate to variations in the pelvic anatomy or wrong 
positioning of the menstrual cup leading to internal 
pressure. These factors could account for case reports of 
hydronephrosis or urinary incontinence. Allergies to the 
materials used in menstrual cups are not common, but 
Figure 3: Proportion of women who wanted to continue menstrual cup use after the study
All studies herein used vaginal cups. In Cheng et al (1995),41 a cup with a valve in the stem was used. In Parker at al (1964),51 one study population had menorrhagia 
(n=46), and the other population had normal flow (n=19). APHRC=African Population and Health Research Center.
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women should be aware of the possibility and keep this 
in mind when starting use. However, for women who 
start using a menstrual cup, discrimination between 
discomfort as part of the normal learning curve 
and pathology might be difficult. Laboratory studies 
have shown contradicting results on the possibility of 
development of TSST-1 in the presence of menstrual 
cups,71–73 but clinical data in humans using cups have so 
far not shown reason for concern.29 The reported risk of 
toxic shock syndrome with use of a menstrual cup seems 
low, with five cases identified via our literature search. 
Although aggregated data on the number of menstrual 
cups sold or used is unavailable, we anticipate the 
number of girls and women using the 199 different 
brands globally is likely to be in the thousands. In the 
USA, the incidence of all types of toxic shock 
syndrome was around 0·8–3·4 per 100 000 population, 
whereas menstrual toxic shock syndrome was reported 
in 6–12 per 100 000 users of high-absorbency tampons 
in 1980.77 Similarly, among women using female barrier 
contraceptives, which also use medical-grade silicone 
or latex products, toxic shock syndrome is low 
(approximately 2·25 cases per 100 000 users per year).78
The combination of an IUD and use of a menstrual cup 
might need further study. Women with IUDs might need 
to consider an alternative option for either family planning 
or menstrual flow. Given the few reports on menstrual 
cups thus far, we cannot yet exclude other issues with the 
use of menstrual cups. Few studies directly compared 
menstrual cups and other menstrual products or 
materials; however, data do not suggest the menstrual cup 
is less effective than other sanitary products. Menstrual 
cups can collect more blood than tampons or sanitary 
pads and have been adopted by women with menorrhagia.51 
The studies we reviewed report that under challenging 
conditions (eg, with little water or privacy), menstrual 
cups can be used. Alternatives to menstrual cups and 
disposable sanitary pads include reusable pads, so far 
assessed in few studies.75,79–81 In Uganda, privacy to dry 
these pads was a challenge, suggesting additional packs 
would be needed to ensure effective laundering.82
Our study had several limitations. We used leakage as a 
primary outcome; however, the outcomes identified in 
the reports and studies reviewed varied by different 
timepoints and designs, prohibiting combination of 
results when directly comparing menstrual cups with 
another item. The quality of studies was a limitation, 
with only three assessed to be of good quality, which will 
potentially have contributed to bias in the meta-analysis. 
Some data were from older studies when reporting 
requirements were less stringent or with menstrual cups 
that are no longer available, from reports not published 
in peer-reviewed journals, and from studies using the 
menstrual cup to assess other topics (eg, understanding 
how uncertainty barriers can be overcome in 
economics,22 use of reusable menstrual products because 
of environmental concerns,37 the association between 
self-objectification and attitudes toward an alternative 
menstrual product47). Recruitment in observational 
studies was not representative or clear. Studies 
mostly depended on self-reporting, which might have 
overestimated use of the menstrual cup. One study 
comparing self-reporting against a conservative but 
objective measure of the colour change of the menstrual 
cup found uptake of use of the menstrual cup was slower 
than self-reported—eg, by 4 months, 75% of recipients 
stated they had started using the cup, whereas only by 
10 months did 75% of menstrual cups show appropriate 
colour change.32 The number of countries where 
menstrual cups were available might be underestimated 
because producers of menstrual cups in low-income and 
middle-income countries might not always have 
websites. Our search was in English, and thus lacked 
information from many countries, such as Russia or 
China. The heterogeneity for the pooled prevalence 
was high in the meta-analyses (I2≥74%), indicating 
inconsistency in outcomes across studies. Given the high 
variability in study design, study period, study population, 
and products examined, this heterogeneity might not be 
unexpected. What proportion of adverse events are 
under-reported is unknown; we did not identify many 
adverse events (one case of toxic shock syndrome) when 
exploring the internet (appendix pp 43–44). The MAUDE 
database only allows searches for the past 10 years. Our 
cost and waste estimates are illustrative and do not 
account for the combined use of menstrual products 
during a period or inflation and production costs.
This systematic review suggests that menstrual cups 
can be an acceptable and safe option for menstrual 
hygiene in high-income, low-income, and middle-
income countries but are not well known. Our findings 
can inform policy makers and programmes that 
menstrual cups are an alternative to disposable sanitary 
products, even where water and sanitation facilities are 
poor. However, provision of information, training, and 
follow-up on correct use might be needed. Further studies 
are needed on cost-effectiveness and environmental 
impact comparing different menstrual products, and to 
examine facilitators for use of menstrual cups, with 
monitoring systems in place to document any adverse 
outcomes.
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